Immunovant FY2025 EPS Estimate Decreased by Lifesci Capital

Immunovant, Inc. (NASDAQ:IMVT) – Research analysts at Lifesci Capital reduced their FY2025 earnings estimates for shares of Immunovant in a research note issued to investors on Sunday, February 23rd. Lifesci Capital analyst S. Slutsky now expects that the company will post earnings per share of ($2.64) for the year, down from their prior forecast of ($2.36). The consensus estimate for Immunovant’s current full-year earnings is ($2.69) per share. Lifesci Capital also issued estimates for Immunovant’s Q4 2025 earnings at ($0.56) EPS.

Several other brokerages have also recently issued reports on IMVT. Guggenheim reduced their target price on shares of Immunovant from $46.00 to $44.00 and set a “buy” rating for the company in a report on Monday, February 10th. Cantor Fitzgerald upgraded shares of Immunovant to a “strong-buy” rating in a research report on Thursday, January 30th. Wolfe Research lowered Immunovant from an “outperform” rating to a “peer perform” rating in a report on Friday, January 3rd. HC Wainwright reiterated a “buy” rating and issued a $51.00 target price on shares of Immunovant in a research report on Friday, February 7th. Finally, Bank of America decreased their price target on shares of Immunovant from $48.00 to $45.00 and set a “buy” rating on the stock in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $45.90.

Immunovant Stock Down 3.2 %

Shares of Immunovant stock opened at $19.78 on Wednesday. The firm has a market capitalization of $3.36 billion, a P/E ratio of -7.55 and a beta of 0.65. Immunovant has a 52 week low of $19.07 and a 52 week high of $39.55. The company has a 50 day moving average price of $22.83 and a 200 day moving average price of $27.10.

Immunovant (NASDAQ:IMVT) last announced its quarterly earnings results on Monday, February 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.08).

Insider Buying and Selling

In other news, CEO Peter Salzmann sold 5,105 shares of the stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $24.10, for a total transaction of $123,030.50. Following the completion of the transaction, the chief executive officer now directly owns 972,992 shares in the company, valued at approximately $23,449,107.20. This represents a 0.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Sciences Ltd. Roivant acquired 16,845,010 shares of Immunovant stock in a transaction that occurred on Monday, January 13th. The stock was bought at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the acquisition, the director now owns 96,650,341 shares in the company, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 27,510 shares of company stock worth $656,886. Insiders own 5.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. KBC Group NV raised its stake in shares of Immunovant by 46.2% in the 3rd quarter. KBC Group NV now owns 1,936 shares of the company’s stock valued at $55,000 after acquiring an additional 612 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Immunovant during the 4th quarter worth approximately $76,000. Assetmark Inc. increased its holdings in Immunovant by 73.8% in the 3rd quarter. Assetmark Inc. now owns 2,891 shares of the company’s stock valued at $82,000 after purchasing an additional 1,228 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Immunovant by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,294 shares of the company’s stock valued at $148,000 after purchasing an additional 934 shares during the period. Finally, Ameriprise Financial Inc. acquired a new position in Immunovant during the fourth quarter worth $221,000. Hedge funds and other institutional investors own 47.08% of the company’s stock.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.